- This event has passed.
De-Intensifying Active Surveillance: Who Can Safely Do Less?
For men on Active Surveillance, one of the biggest questions is not just whether more testing is possible, but how much testing is really needed. Active Surveillance is meant to help men avoid or delay unnecessary treatment while still keeping prostate cancer safely watched. But not every man needs the same schedule forever.
In this timely ASPI program, Michael S. Leapman, MD, MHS, of Yale University, will discuss whether some men on Active Surveillance may be able to safely do less testing over time — including fewer biopsies, fewer MRIs, or longer intervals between checkups — while still staying carefully monitored.
JOIN THE CONVERSATION
Hear from Michael S. Leapman, MD, MHS, as he discusses a question many men on Active Surveillance eventually face: Can I safely do less?
Dr. Leapman, a urologic oncologist at Yale and Clinical Program Leader of the Prostate & Urologic Cancers Program at Yale Medicine, will talk about how doctors think about adjusting follow-up over time. He will explore what may make some men good candidates for less frequent testing, and how MRI findings, biomarkers, PSA patterns, and PI-RADS scores may help guide those decisions.
The conversation will focus on how Active Surveillance can remain safe while also becoming more personalized, so men are not doing more testing than they need.
Saturday, July 25, 2026 • 12:00 PM Eastern Time
Patients are welcome to submit questions in advance to
contactus@aspatients.org.
In addition, there will be dedicated time for live Q&A following the presentation.
ABOUT OUR SPEAKER
Michael S. Leapman, MD, MHS, is a urologic oncologist at Yale University who specializes in prostate, bladder, testicular, and kidney cancers. He is a member of Yale Cancer Center and serves as Clinical Program Leader of the Prostate & Urologic Cancers Program at Yale Medicine.
Dr. Leapman’s work focuses on improving care and decision-making for men with prostate cancer, including how patients and doctors choose among surgery, radiation therapy, and Active Surveillance. His research has also looked at how newer tools may help predict whether a prostate cancer is likely to behave more aggressively, helping patients receive care that better fits their individual situation.
WHAT WE’LL EXPLORE
How often do men on Active Surveillance really need biopsies, MRIs, and other testing? When might it be safe to spread those tests farther apart — and when is closer follow-up still important?
This program will look at how Active Surveillance can be adjusted over time. Dr. Leapman will discuss how doctors may consider a man’s age, cancer features, MRI results, PSA patterns, biomarkers, and overall health when deciding how closely he needs to be followed.
The conversation will also touch on MRI scores such as PI-RADS, and how imaging may help doctors understand whether a man’s cancer appears stable or whether there may be a higher chance that future testing could show a more concerning grade.
For many men, Active Surveillance can bring peace of mind, but it can also bring repeated testing, anxiety, and difficult decisions about when to biopsy or scan again. This meeting is designed to help patients and families better understand how Active Surveillance can stay safe while becoming more personal.
Saturday, July 25, 2026 • 12:00 PM Eastern Time